Faced with fierce competition, price declines and reimbursement pressure in the U.S. Bayer (Leverkusen, Germany) has decided to duck out of the diabetes care market and focus on its life sciences organizations, primarily pharmaceuticals. The company said it plans to sell its diabetes business to Panasonic Healthcare (Tokyo) in a deal valued at €1 billion ($1.13 billion).